Top Markets
#1 MowCat MowCat +48.67%
#2 Bitway Bitway +30.21%
#3 Velvet Velvet +24.66%
#4 Fake World Assets Fake World Assets +21.42%
#5 aPriori aPriori +21.38%
#6 OVERTAKE OVERTAKE +18.72%
#7 Biconomy Biconomy +15.83%
#8 Zerebro Zerebro +14.02%
#9 Derive Derive +11.98%
#10 Perle Perle +11.26%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Rangering i aksjer #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Aksjekurs
$0.6379482
Sist synkronisert: 2023-05-22
Markedsverdi
$5.98M
Endring (1 dag)
-0.44%
Endring (1 år)
0.00%
Land
FR
Handel Nicox S.A. (COX)

Kategori

Healthcare
Inntekter for Nicox S.A. (COX)
Inntekter i 2026 TTM: 0
Ifølge Nicox S.A. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Nicox S.A. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE